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Abstract
Background: Drug resistance in breast cancer is the major obstacle to effective treatment with chemotherapy.
While upregulation of multidrug resistance genes is an important component of drug resistance mechanisms in
vitro, their clinical relevance remains to be determined. Therefore, identifying pathways that could be targeted in
the clinic to eliminate anthracycline-resistant breast cancer remains a major challenge.
Methods: We generated paired native and epirubicin-resistant MDA-MB-231, MCF7, SKBR3 and ZR-75-1 epirubicin-
resistant breast cancer cell lines to identify pathways contributing to anthracycline resistance. Native cell lines were
exposed to increasing concentrations of epirubicin until resistant cells were generated. To identify mechanisms
driving epirubicin resistance, we used a complementary approach including gene expression analyses to identify
molecular pathways involved in resistance, and small-molecule inhibitors to reverse resistance. In addition, we
tested its clinical relevance in a BR9601 adjuvant clinical trial.
Results: Characterisation of epirubicin-resistant cells revealed that they were cross-resistant to doxorubicin and
SN-38 and had alterations in apoptosis and cell-cycle profiles. Gene expression analysis identified deregulation
of histone H2A and H2B genes in all four cell lines. Histone deacetylase small-molecule inhibitors reversed
resistance and were cytotoxic for epirubicin-resistant cell lines, confirming that histone pathways are associated
with epirubicin resistance. Gene expression of a novel 18-gene histone pathway module analysis of the BR9601
adjuvant clinical trial revealed that patients with low expression of the 18-gene histone module benefited from
anthracycline treatment more than those with high expression (hazard ratio 0.35, 95 % confidence interval
0.13–0.96, p = 0.042).
Conclusions: This study revealed a key pathway that contributes to anthracycline resistance and established
model systems for investigating drug resistance in all four major breast cancer subtypes. As the histone
modification can be targeted with small-molecule inhibitors, it represents a possible means of reversing
clinical anthracycline resistance.
Trial registration: ClinicalTrials.gov identifier NCT00003012. Registered on 1 November 1999.
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Background
Breast cancer is the second leading cause of cancer
death for women. Most patients present with early dis-
ease and are treated with surgery, often followed by
adjuvant radiotherapy and chemotherapy with or with-
out endocrine therapy or trastuzumab given with cura-
tive intent. Nevertheless, 40–50 % of high-risk patients
treated with adjuvant chemotherapy ultimately relapse
as a result of having resistant disease [1]. Despite the ad-
vent of targeted therapies, chemotherapy is also central
to the treatment of women with metastatic disease,
who often respond to palliative chemotherapy but in
due course relapse due to drug resistance, including
cross-resistance to structurally unrelated anti-cancer
drugs [2].
The taxanes and anthracyclines are widely used as
adjuvant therapy as well as in metastatic cancer. Both
target rapidly proliferating cancer cells. The taxanes
interfere with microtubule depolymerisation, causing
cell-cycle arrest [3, 4], whereas anthracyclines introduce
DNA breaks, form free radicals and covalently bind type
II topoisomerase (Topo II)–DNA complexes [5]. The
taxanes and anthracyclines are both natural products
and susceptible to resistance mediated by over-
expression of the multidrug transporter P-glycoprotein.
A well-established in vitro mechanism of resistance
involves activity of multidrug resistance genes 1 and 2/3
(MDR1 and MDR2/3, respectively), which bind non-
specifically to multiple drugs and actively export them
across the cellular membrane [6, 7]. Although this re-
sults in decreased intra-cellular drug concentrations and
cytotoxicity, the clinical relevance of MDR genes remains
to be determined. Other mechanisms include reduced
Topo activity [8, 9], reduced Fas ligand expression [10]
and downregulation of TP53 expression [11]. However,
the molecular drivers of clinical anthracycline resistance
remain largely unknown. We previously identified dupli-
cation of centromeric region on chromosome 17 (CEP17),
a surrogate marker of chromosomal instability, as a pre-
dictive marker of clinical anthracycline sensitivity [12–14].
However, identifying pathways that could be targeted in
the clinic to eliminate anthracycline-resistant breast can-
cer remains a major challenge.
The aim of this study was to establish anthracycline-
resistant breast cancer cell lines to (1) identify path-
ways driving resistance that are common to all breast
cancers, regardless of their oestrogen receptor (ER)
and human epidermal growth factor receptor 2 (HER2)
status; (2) discover a predictive biomarker of anthracycline
benefit; and (3) investigate alternative treatment options
for patient groups that are not expected to respond to
anthracycline regimens. Cell lines were chosen to re-
flect four major breast cancer subtypes [15, 16]:
MCF7 (ER+/HER2−, luminal A), ZR-75-1 (ER+/HER2+,
luminal B), SKBR3 (ER−/HER2+, HER2-amplified) and
MDA-MB-231 (ER−/progesterone receptor–negative
[PR−]/HER2−, triple-negative), and they were exposed
to increasing concentrations of epirubicin until resistant
cells were generated. To identify mechanisms driving epir-
ubicin resistance, we used complementary approaches, in-
cluding gene expression analyses to identify signalling
pathways involved in resistance and small-molecule inhib-
itors to reverse resistance. We demonstrated that a his-
tone H2A- and H2B-containing module was associated
with epirubicin resistance and that small-molecule inhibi-
tors targeting histone pathways induced cytotoxicity in all
epirubicin-resistant cell lines. Most importantly, the iden-
tified mechanism of resistance was recapitulated in the
BR9601 clinical trial, where the patients with low expres-
sion of the histone module benefited from anthracycline
treatment compared with patients with high expression of
the same module (hazard ratio [HR] 0.35, 95 % confidence
interval [CI] 0.13–0.96, p = 0.042). Thus, in our study, we
identified that chromatin remodelling represents an im-
portant mechanism of anthracycline resistance in breast
cancer and established a reliable in vitro model system for
investigating anthracycline resistance in all four breast
cancer subtypes. As the histone modification can be tar-
geted with small-molecule inhibitors, it presents a possible
means of reversing clinical anthracycline resistance.
Methods
BR9601 trial
The BR9601 trial (ClinicalTrials.gov identifier
NCT0003012) investigators recruited 374 pre- and
post-menopausal women with completely excised, his-
tologically confirmed breast tumours and a clear indi-
cation for adjuvant chemotherapy. Patients were
randomised between 8 cycles of CMF (intravenous
cyclophosphamide 750 mg/m2, methotrexate 50 mg/m2
and 5-fluorouracil 600 mg/m2) every 21 days, and E-CMF
(4 cycles of epirubicin 100 mg/m2 every 21 days followed
by 4 cycles of the same CMF regimen) [17] (Additional
file 1: Figure S1). The protocol was approved by cen-
tral and local ethics committees, and each patient pro-
vided written informed consent before randomisation.
For the present analysis, tissue blocks were retrieved
and RNA was extracted. The primary outcomes of the
BR9601 study were relapse-free survival and OS, al-
though distant relapse-free survival (DRFS) was also
reported [17].
Cell culture
Breast cancer cell lines (MDA-MB-231, MCF7, ZR-75-1,
SKBR3) were purchased from the American Type
Culture Collection (Manassas, VA, USA) and cultured in
Dulbecco’s modified Eagle’s medium (except SKBR3, cul-
tured in RPMI 1640 medium) supplemented with 10 %
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heat-inactivated foetal bovine serum and Gibco 1 % L-
glutamine (Thermo Scientific, Burlington, ON, Canada).
Epirubicin-resistant cell lines were generated by expos-
ing native cells to increasing concentrations of epirubi-
cin with an initial concentration set at 0.5 nM.
Resistance was defined when the half-maximal inhibitory
concentration (IC50) value superseded the IC50 value of
the corresponding native cell line and resistant cells
could not tolerate further increase in drug concentra-
tion. Drug resistance and cross-resistance were determined
by exposing cells to drug concentrations ranging from 0.3
to 3000 nM for 72 h. Cell viability was determined using
the Cell Counting Kit-8 (CCK-8; Dojindo Molecular Tech-
nologies/Cedarlane Laboratories, Burlington, ON, Canada).
IC50 values were calculated using Prism 5 software (Graph-
Pad Software, La Jolla, CA, USA).
Flow cytometry
For cell-cycle analysis, cells were synchronised by the
double-thymidine block [18] and incubated with di-
methyl sulphoxide (DMSO) or epirubicin doses estab-
lished for each cell line: 25 nM for MDA-MB-231, 30
nM for MCF7, 15 nM for SKBR3 and 10 nM for ZR-
75-1. Cells were collected at 48 h, fixed with 80 %
ethanol and incubated with 2 mg/ml RNase A and
0.1 mg/ml propidium iodide (Sigma-Aldrich, Oakville,
ON, Canada) before analysis. For apoptosis experi-
ments, cells were treated with DMSO or epirubicin at
the concentrations described above and collected at
72 h for staining with annexin V apoptosis detection
eFluor 450 (eBioscience, San Diego, CA, USA). Data
were collected using a FACSCanto II flow cytometer
and FACSDiva software (BD Biosciences, Mississauga,
ON, Canada) and analysed using FlowJo software
(Treestar, Ashland, OR, USA).
Cell proliferation
Cells were cultured in the presence or absence of epirubi-
cin for up to 96 h (see Flow cytometry section above for
epirubicin concentrations). Cells were collected at 24, 48,
72 and 96 h and counted using a Vi-CELL Cell Viability
Analyzer (Beckman Coulter, Mississauga, ON, Canada).
Data were analysed using GraphPad Prism 5 software.
Microarray
Illumina HumanHT-12 v4 BeadChips (Illumina, San
Diego, CA, USA) were used for the whole genome
microarray analysis by the UHN Microarray Centre,
Toronto, ON, Canada. Total RNA was extracted with
the RNeasy Mini Kit (Qiagen, Toronto, ON, Canada)
and used for profiling gene expression changes. Raw
data (Gene Expression Omnibus accession number
[GEO:GSE54326]) were normalised with the R3.0.0 lumi
package using simple scaling normalisation; the 10 %
most variable probes were retained for differential
analysis using the genefilter package. Differentially
expressed probes were identified using limma with a
Benjamini–Hochberg corrected p value cut-off of 0.05.
Network-based analysis
To identify functionally relevant modules, genes demon-
strating consistent directionality of significant expression
changes were analysed using the Cytoscape Reactome
Functional Interaction (FI) plugin in Cytoscape 2.8.3.
Symbols were loaded as a gene set and interactions from
the FI network 2012 version, including FI annotations
and linker genes. Network modules were identified using
spectral clustering and pathway enrichment computed
for each module using the Reactome FI plugin functions.
Reactome pathways exhibiting false discovery rate (FDR)
values less than 0.01 were considered enriched.
Pharmaceutical inhibitors
All inhibitors were provided by the drug discovery group
at the Ontario Institute for Cancer Research (Toronto,
ON, Canada). Cells were seeded at 1000–1500 cells/well
into 384-well plates (Greiner Bio-One, Mississauga, ON,
Canada). After 24 h, resistant cells were exposed to
epirubicin at the selection doses established (see Flow
cytometry section above), then exposed to histone dea-
cetylase (HDAC) inhibitors (HDACi) dissolved in DMSO
in 12 concentrations ranging from 0.0026 to 10 μM
using HP D300 digital compound dispenser (Tecan
Systems, San Jose, CA, USA). The DMSO concentration
did not exceed 0.5 % in the final drug solution. After 72 h,
the effects of inhibitors were determined using CellTiter-
Glo Luminescent Cell Viability Assay (Promega, Madison,
WI, USA) and the Wallac EnVision 2104 Multilabel
Reader (PerkinElmer, Woodbridge, ON, Canada). Raw
data were normalised to negative (media) and positive
(20 μM staurosporine) controls and analysed using
GraphPad Prism 5.
Quantitative RT-PCR
RNA was isolated from cultured cell lines using the
RNeasy Mini Kit (Qiagen, Toronto, ON, Canada). A total
of 20 ng of RNA was analysed using TaqMan gene expres-
sion assays (HIST1H2BD, Hs00371070_m1; HIST1H2BK,
Hs00955067_g1; HIST1H2AC, Hs00185909_m1) and
EXPRESS One-Step Superscript qRT-PCR universal kit
according to manufacturer’s protocol (Life Technologies,
Burlington, ON, Canada). Reactions were run using
Applied Biosystems ViiA 7 Real-Time PCR instrument
and software (Life Technologies). Transcript levels were
quantified from the standard curve generated from the
control Universal Human Reference RNA samples
(Agilent, Mississauga, ON, Canada). Statistical significance
was determined using an unpaired t test.
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Immunoblotting
Whole-cell lysates (WCL) were prepared in radioimmu-
noprecipitation assay (RIPA) buffer supplemented with
cOmplete Mini Protease and PhosSTOP phosphatase
inhibitors (Roche, Laval, QC, Canada). For cell line
characterisation, 10–50 μg of total protein was run
on 4–20 % Mini-PROTEAN TGX Precast Gels (Bio-
Rad Laboratories, Mississauga, ON, Canada). For histones,
cells were collected in 0.1 % Nonidet P-40 in phosphate-
buffered saline to release nuclei. WCL were prepared by
adding equal volumes of 2× RIPA buffer supplemented
with 25 U of Benzonase Nuclease (Sigma-Aldrich) and
cOmplete Mini Protease Inhibitor Cocktail (Roche), incu-
bating on ice for 30 minutes and sonicating for 15 minutes
with 30-second on-off intervals. Twenty micrograms of
WCL were run on a 12 % gel. A list of primary antibodies
used in immunoblotting is provided in Additional file 1:
Table S5. Signals were developed with BM Chemilumines-
cence Blotting Substrate (POD) (Roche) and a ChemiDoc
imaging system (Bio-Rad Laboratories).
Small interfering RNA transfection of ZR75-1- and
MDA-MB-231-resistant cells
For CCK-8 assays, a total of 7 × 104 ZR75-1 epirubicin-
resistant cells and MDA-MB-231 epirubicin-resistant
cells were transfected with Lipofectamine RNAiMAX
(Life Technologies) and 10 nM Dharmacon ON-
TARGETplus siRNA reagent human SMARTpool (GE
Healthcare, Lafayette, CO, USA) targeting HIST1H2AC
(L-011435-01-0005), HIST1H2BK (L-013323-02-0005)
or both according to the manufacturer’s instructions.
Negative controls included media only, Lipofectamine
only or mock transfection with non-targeting small
interfering RNA (siRNA; D-001810-10-05). Cells were
exposed to 0.3–3000 nM epirubicin for 72 h before their
viability was determined using the CCK-8 kit. For flow
cytometric analyses, 2 × 105 cells were plated in 6-well
plates and transfected with 10 nM siRNA or control as
described above. Samples were collected at 72 h for
quantitative real-time polymerase chain reaction (qRT-
PCR) and flow cytometric analyses.
nCounter CodeSet and data pre-processing
The nCounter gene expression CodeSet (NanoString
Technologies, Seattle, WA, USA) included 7 genes within
the histone module and 11 additional genes that were iden-
tified in the KEGG PATHWAY database [19] as being im-
portant for histone function (Additional file 1: Table S6).
HIST1H2AC was excluded from the CodeSet because
probes cross-hybridised to other genes. All 18 genes were
functionally related (Additional file 1: Figure S6). Messenger
RNA (mRNA) CodeSets were processed on nCounter
according to the manufacturer’s instructions. Raw mRNA
abundance data were pre-processed using the
NanoStringNorm R package (v1.1.19; Additional file 2:
Methods). A range of pre-processing schemes was
assessed to optimise normalisation parameters as previ-
ously described (Haider S., Yao C. Q., Sabine V. S.,
Grzadkowski M., Starmans M. H. W., Wang J., Nguyen
F., Moon N. C., Lin X., Drake C., Crozier C. A., Brookes
C. L., van de Velde C. J. H., Hasenburg A., Kieback D. G.,
Markopoulos C. J., Dirix L. Y., Seynaeve C., Rea D. W.,
Kasprzyk A., Lambin P., Lio P., Bartlett J. M. S., Boutros P.
C.: Using pathways for cross-disease biomarker discovery,
in preparation).
Survival modelling
To assess whether individual genes are prognostic of sur-
vival, each gene was median dichotomised into low- and
high-expression groups and univariate Cox proportional
hazards models were fit (Additional file 1: Figure S7). Sur-
vival analysis of clinical variables modelled age as binary
variable (dichotomised at age >50 years), while nodal status,
pathological grade, ER status and HER2 status were mod-
elled as ordinal variables (Additional file 1: Figure S1B).
Tumour size was treated as a continuous variable.
mRNA network analysis
We hypothesised that integrating molecular modules
could improve residual risk prediction relative to DRFS
and OS. For each module, we calculated a module dysreg-
ulation score (Additional file 2: Methods), which we used
in a univariate Cox proportional hazards model. A strati-
fied fivefold cross-validation approach was applied, and
models were trained in the training cohort and validated
in the kth testing cohort using 10-year DRFS as an end
point. All survival modelling was performed on DRFS and
OS in the R statistical environment with the survival pack-
age (v2.37-7). Treatment by marker interaction term was
calculated using Cox proportional hazards model.
Results
Generation and characterisation of epirubicin-resistant
breast cancer cell lines
Resistant cell lines generated from epirubicin-sensitive
native cell lines MDA-MB-231, MCF7, SKBR3 and ZR-
75-1 exhibited 7- to 67-fold increased resistance to epir-
ubicin (Fig. 1). We tested whether epirubicin-resistant
cell lines are cross-resistant to doxorubicin, paclitaxel,
docetaxel, SN-38 and carboplatin, drugs used in breast
cancer clinical trials. All four epirubicin-resistant cell
lines were resistant to doxorubicin (Fig. 1b). While
MDA-MB-231, MCF7 and ZR-75-1 epirubicin-resistant
cells were not taxane-resistant, SKBR3 epirubicin-
resistant cells were cross-resistant to both paclitaxel and
docetaxel (Fig. 1b). MDA-MB-231 and SKBR3 cells were
cross-resistant to SN-38, whereas MCF7 and ZR-75-1
tolerated only small increases in SN-38 concentrations.
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None of the cell lines were cross-resistant to carboplatin
(Fig. 1b).
Epirubicin-resistant cells showed slightly decreased
levels of ER and PR in ZR-75-1 cells compared with
native cells. The levels of epidermal growth factor re-
ceptor, HER2 and HER3 also remained unchanged
(Fig. 2). Interestingly, we observed small amounts of
HER2 protein in MCF7 cell lines, which was not evi-
dent by flow cytometry (Additional file 1: Figure S8),
in line with classifying this cell line as being HER2−
[20]. MDR1 was upregulated only in resistant SKBR3
cells, which may explain their cross-resistance to tax-
anes (Fig. 1b). Topo IIα expression was downregu-
lated in epirubicin-resistant ZR-75-1 cells (Fig. 2). No
changes in MDR or Topo IIα were observed in
epirubicin-resistant MDA-MB-231 and MCF7 cell
lines. These results suggest that anthracycline resist-
ance is not MDR-driven for three of four cell lines
and that epirubicin-resistant cell lines remained un-
altered with respect to the expression of conventional
breast cancer biomarkers.
To determine cell-doubling time, we cultured cells
with or without epirubicin for up to 96 h. In the absence
of epirubicin, the native MDA-MB-231 and MCF7 cell
populations doubled every 25 h and 29 h, respectively
(Additional file 1: Table S1), whereas native SKBR3 and
ZR-75-1 cells grew more slowly, doubling every 45 h
and 50 h, respectively. In the presence of epirubicin,
doubling time increased 2.8-fold for MDA-MB-231
(p = 0.0371), 2.5-fold for MCF7 (non-significant), 1.3-
fold for SKBR3 (p = 0.0494) and 1.9-fold for ZR-75-1
(p = 0.0258) for native cells. In contrast to the native cell
lines, there were no marked changes in the doubling time
of the resistant cells, regardless of whether epirubicin was
added (Additional file 1: Table S1). Interestingly, in the ab-
sence of epirubicin, none of the resistant cells proliferated
as rapidly as native cells, indicating that epirubicin selec-
tion induced permanent changes in resistant cells.
Impaired apoptosis in anthracycline-resistant cells
To assess the effects of epirubicin on apoptosis, apop-
totic cells were scored by flow cytometry after 72 h of
Fig. 1 Characterisation of epirubicin-resistant cell lines. Native and resistant cells were exposed to drug concentrations ranging from 0.3 to 3000
nM. Cell viability was determined 72 h later by Cell Counting Kit-8 assay. a Percentage of live cells relative to dimethyl sulphoxide control was
plotted against epirubicin concentration. Black = native cells, magenta = resistant cells. b Half-maximal inhibitory concentration (IC50) values in
nanomolar concentrations ± standard deviation. Resistance factor is shown in parentheses and represents resistant IC50/native IC50
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exposure to epirubicin. The apoptotic index was consist-
ently lower for resistant cells than for native controls
(Table 1). In particular, MDA-MB-231 and SKBR3
epirubicin-resistant cells required a substantially higher
concentration of epirubicin (1000 nM) to induce apoptosis.
Even at this concentration of epirubicin, the apoptotic index
was still nearly 50 % less than for the native cells (Table 1).
Resistant cell lines overcome epirubicin-induced G2/M arrest
Cells were synchronised before exposure to DMSO or
epirubicin. All DMSO-treated cell lines progressed
through the cell cycle (Fig. 3). When 25 nM and 10 nM
epirubicin were added to the MDA-MB-231 and ZR-75-
1 cell lines, respectively, native cells arrested in G2/M
phase, whereas resistant cells progressed through
(Fig. 3a, c). When 30 nM and 15 nM epirubicin were
added to the MCF7 and SKBR3 cell lines, respect-
ively, we observed only a modest effect on the cell
cycle (Fig. 3b, d). This necessitated increasing epirubi-
cin concentrations to 100 nM, at which level native
cells arrested in G2/M phase but with minimal effect
on the epirubicin-resistant cells (Fig. 3b, d). There-
fore, overcoming a G2/M block may be part of the
process leading to epirubicin resistance.
Gene expression analyses identify histone H2A- and
H2B-containing pathways as potential functional drivers
of epirubicin resistance
Whole genome expression analysis revealed 209 genes in
common, differentially expressed between all four pairs
of native and epirubicin-resistant cell lines (Fig. 4a). Of
these, 61 genes were regulated in the same direction in
all four cell lines; of these, 26 genes were consistently
upregulated and 35 were consistently downregulated
Fig. 2 Expression of conventional breast cancer biomarkers and
selected multidrug resistance genes. Cell lysates were prepared in
radioimmunoprecipitation assay buffer supplemented with cOmplete
Mini protease inhibitor and PhosSTOP phosphatase inhibitor.
Quantities (10–50 μg) of total protein were run on a 10 % gel
(MDR1), 4–20 % precast gels (epidermal growth factor receptor
[EGFR], oestrogen receptor [ER], progesterone receptor [PR], type II
topoisomerase [TOPO IIα]) and Any kD Mini-PROTEAN TGX Precast
Protein Gels (human epidermal growth factor receptor 2 [HER2], HER3),
transferred onto polyvinylidene fluoride membrane and developed
using chemiluminescence substrate. Nat native, Epi-R epirubicin-
resistant, GAPDH glyceraldehyde-3-phosphate dehydrogenase
Table 1 Percentages of apoptotic cells following a 72-h
epirubicin treatment
Cell line Control Epirubicin concentration
MDA-MB-231 DMSO 1 nM 25 nM 1000 nM
Native 18 % 17 % 41 % 94 %
25 nM-R 10 % 10 % 8 % 50 %
MCF7 DMSO 1 nM 30 nM 1000 nM
Native 32 % 29 % 49 % 77 %
30 nM-R 20 % 24 % 23 % 78 %
SKBR3 DMSO 1 nM 15 nM 1000 nM
Native 22 % 26 % 24 % 59 %
15 nM-R 18 % 17 % 17 % 34 %
ZR-72-1 DMSO 1 nM 10 nM 1000 nM
Native 36 % 44 % 47 % 71 %
10 nM-R 29 % 28 % 29 % 62 %
DMSO dimethyl sulphoxide; DRFS, distant relapse-free survival
Apoptotic cells = annexin V–positive. Debris and necrotic cells (annexin
V–negative, 7-aminoactinomycin D–positive) were gated out. Percentages
reported are derived from a single experiment; at least two independent
experiments were done for each cell line
Bold data denotes the different concentrations of epirubicin used for each cell
line
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(Additional file 1: Table S2 and Figure S3). These 61
genes were used to generate a gene interaction network
and identify candidate pathways involved in epirubicin
resistance. A minimal set of linker genes was used to
connect the network. Identifying clustered genes within
the network revealed four modules (Additional file 1:
Figure S2); however, only modules 1 and 2 contained
significantly enriched pathway annotations with a FDR
less than 0.01. Module 1 contained three histone genes
(HIST1H2AC, HIST1H2BK and HIST1H2BD) and sev-
eral genes involved in RNA processing and mitosis
(Fig. 4b). Importantly, all three histone genes were up-
regulated in all four cell lines and directly intercon-
nected without linker genes. Within module 1,
significantly enriched pathways included cell-cycle regu-
lation (Fig. 4e), consistent with our results shown in
Fig. 3. Module 2 contained three directly connected
genes (TACC3, AURKA and NFKBIA) involved in aurora
A kinase signalling. While NFKBIA was upregulated,
TACC3 and AURKA were downregulated.
We focused on histone-containing module 1 because
all three histones were upregulated, tightly intercon-
nected without linker genes and implicated in several
molecular pathways. Elevated levels of all three histone
transcripts were validated by qRT-PCR (Fig. 4c). Because
antibodies specific to individual histone variants are not
commercially available, we assessed protein expression
using pan H2A and H2B antibodies. We observed no
difference in the total H2A and H2B levels between re-
sistant and native cell lines (Fig. 4d). Overall, our find-
ings suggest that histone upregulation is a common
event associated with epirubicin resistance in breast can-
cer cells and that histone-related pathways might be
functional drivers of epirubicin resistance.
Fig. 3 Resistant cell lines overcome epirubicin-induced G2/M arrest. a–d Cells were synchronised by a double-thymidine block and treated with
dimethyl sulphoxide or epirubicin at selection doses established for each resistant cell line: 25 nM epirubicin to MDA-MB-231, 30 nM epirubicin to
MCF7, 15 nM epirubicin to SKBR3 and 15 nM epirubicin to ZR-75-1. Epirubicin concentration was increased to 100 nM for MCF7 and SKBR3 cells
because G2/M block was not observed at the lower doses of epirubicin. Cells were collected at 48 h, stained with propidium iodide and analysed
by flow cytometry. Debris was gated out. GAPDH glyceraldehyde-3-phosphate dehydrogenase
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Fig. 4 Network-based analysis of epirubicin-resistant (EpiR) cell lines. a Venn diagram of genes with significant changes in expression in breast
cancer cell lines. b Histone module identified in Functional Interaction network analysis. Coloured rings denote genes demonstrating consistent
changes across all four cell lines. Red rings = upregulated genes, green rings = downregulated genes, diamonds = linker genes. c Quantitative
real-time polymerase chain reactions performed on RNA isolated from native and epirubicin-resistant cell lines. Bar graphs indicate average
quantitative means, while error bars represent standard error of the mean. p Values were calculated using unpaired t test. ns non-significant.
d Immunoblotting of total H2A and H2B histone proteins in native and epirubicin-resistant cell lines. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as a housekeeping control. e Reactome pathways significantly enriched within the module shown in (b)
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Histone gene knockdown is insufficient to resensitise
breast cancer cells to epirubicin
We performed a series of gene knockdown experiments
in MDA-MB-231- and ZR-75-1-resistant cells in which
HIST1H2AC, HIST1H2BK or both were silenced before
cells were exposed to epirubicin (Fig. 5a and b). A de-
crease in histone transcripts was confirmed by qRT-PCR
(summarised in Additional file 1: Table S3). HIST1H2BK,
rather than HIST1H2BD, was selected because high tran-
script levels of this variant were associated with poor
survival of patients with breast cancer in our in silico
analysis (data not shown; for online tool, see [21]). Inter-
estingly, transient knockdown of either histone alone, or
both, did not increase their sensitivity to epirubicin
(Fig. 5a and data not shown), although epirubicin IC50
values were slightly reduced for ZR-75-1 upon histone
knockdown (Fig. 5b). We further investigated whether
the histone variant knockdown had an effect on cell
cycle and apoptosis and found that neither process was
severely affected (Fig. 5d and e). These results suggest
that other histone variants might have compensated for
the loss of HIST1H2AC and/or HIST1H2BK activity and
that our efforts should be focused on targeting the func-
tion of the module rather than a few of its genes.
Histone module is a clinical marker of anthracycline
sensitivity
The prognostic significance of the 18-gene histone mod-
ule was tested on the entire BR9601 clinical cohort,
regardless of allocated adjuvant chemotherapy. High his-
tone module expression was associated with reduced
DRFS (HR 2.64, 95 % CI 1.7–4.09, p = 1.44 × 10−5), indi-
cating that elevated histone module is prognostic of poor
DRFS on chemotherapy.
Next, we analysed the differential effects of the histone
module on breast cancer–specific overall survival (OS)
and DRFS between patients in the BR9601 trial receiving
an anthracycline (E-CMF) and those given CMF alone
by assessing HRs and treatment by marker interactions.
Patients whose tumours had low gene expression had in-
creased OS (HR 0.38, 95 % CI 0.19–0.76, p = 0.005)
when treated with E-CMF compared with patients
treated with CMF alone. Conversely, there was no appar-
ent differential benefit of E-CMF vs. CMF in patients
with high histone module expression for OS (HR 0.97,
95 % CI 0.57–1.64, p = 0.91) (Fig. 6a). Similarly, pa-
tients whose tumours had low histone module expres-
sion had increased DRFS (HR 0.35, 95 % CI 0.17–0.73,
p = 0.0048) when treated with E-CMF compared with
patients treated with CMF alone (Fig. 6a). There was
no apparent differential benefit of E-CMF vs. CMF in
patients with high histone module expression for
DRFS (HR 0.96, 95 % CI 0.58–1.59, p = 0.87). In multi-
variate analysis, after adjustment for HER2 status,
nodal status, age, grade, size and ER status, the treat-
ment by marker interaction showed no statistical differ-
ence for OS (HR 0.50, 95 % CI 0.19–1.31, p = 0.159). The
likelihood of DRFS remained low among patients with
low histone module gene expression compared with
patients with high expression (HR 0.35, 95 % CI
0.13–0.96, p = 0.042) (Fig. 6b).
HDACi induce cytotoxicity in epirubicin-resistant
cells lines
Gene expression analysis identified the histone module
as significantly altered and possibly functionally required
for epirubicin resistance. Consequently, we tested
whether alteration of histone activity would sensitise
cells to epirubicin using HDACi, which reverse histone
hypoacetylation and permit transcriptional activation.
Twenty-four HDACi were tested against the native and
epirubicin-resistant cell lines. For resistant cell lines, all
inhibitors were tested in the presence of selection doses
of epirubicin. Positive hits were defined as compounds
that exhibited cytotoxicity in at least 50 % of the popula-
tion and had an IC50 less than 5 μM in all eight cell
lines. We found that 14 HDACi were cytotoxic to all na-
tive and epirubicin-resistant cells lines (Additional file 1:
Table S4). Importantly, three of four resistant cell lines
were more sensitive to epirubicin than to native cells
when several HDACi were supplied. The results pro-
vided in Fig. 7a show the effects of one HDACi, panobi-
nostat, on all four cells lines. Interestingly, epirubicin-
resistant MDA-MB-231 cells, but not MCF7 or ZR-75-1
cells, were more sensitive to panobinostat than native
cells. In contrast, epirubicin-resistant SKBR3 cells were
less sensitive to the HDACi than native cells, possibly
due to the upregulation of efflux pumps (Fig. 2). Fur-
thermore, because HDACi target different HDACs and
none of the HDACi ubiquitously resensitised all four re-
sistant cell lines (Additional file 1: Table S4), it appears
that different classes of HDACs are involved in anthra-
cycline resistance, possibly in a breast cancer subtype-
specific manner. Collectively, our data reveal a previ-
ously unrecognised role of histones and suggests that
H2A and H2B histones are involved in clinical anthracy-
cline resistance.
Discussion
Anthracycline resistance is a major obstacle to the
effective treatment of women with breast cancer.
Although various mechanisms may contribute to anthra-
cycline resistance, including activation of drug trans-
porters, reduced activity of Topo IIα and inhibition of
apoptosis, the majority of the molecular mechanisms in-
volved in clinical drug resistance remain unknown.
Using a panel of cell lines representative of the major
molecular subtypes of breast cancer, we have shown that
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deregulation of histones involved in chromosome main-
tenance, epigenetic pathways, cell division and gene
regulation is observed consistently in epirubicin-
resistant cell lines. This observation was then validated
clinically in the BR9601 adjuvant clinical trial.
Histone H2A and H2B variants are emerging as media-
tors of drug sensitivity and resistance in cancer [22, 23].
We have shown that the dysregulation of histones is as-
sociated with increased cell-cycle progression, specific-
ally the release of a G2/M cell-cycle block in the
presence of epirubicin, and with a reduction in apoptotic
cell death. Interestingly, transcriptional knockdown of
the two histone variants contributing to the dysregula-
tion signature did not completely sensitise cells to
anthracycline, possibly for a few reasons. First, although
the transcript levels were reduced by 6–53 %, it is pos-
sible that the protein levels remained unchanged during
our experimental window. We were not able to assess
protein expression of each specific variant, because
antibodies are not yet commercially available. Second,
even if the protein levels were sufficiently diminished,
it is still possible that other histone variants function-
ally substituted for HIST1H2AC and HIST1H2BK be-
cause there are 9 H2A and 11 H2B non-allelic
histone variants [24]. Third, the module contains 16
other genes that perform together with the histone
genes in this functional module. This notion is shift-
ing away from the previous efforts that were focused
on discovering single genes as biomarkers by using
fold-change differences in gene expression as the
means of selecting promising biomarker candidates.
Instead, the FI network approach relies on the
strength of the gene-to-gene interactions and is based
on how closely the genes are functionally related.
This entire module was identified to be a predictive
biomarker of anthracycline benefit, which allowed us
to focus our efforts on identifying a drug that could
target the function of an entire module rather than
one of its components. Indeed, using a small-
molecule inhibitor screen, we have shown that drugs
directly targeting histone function (HDACi as well as
cell-cycle inhibitors; data not shown) are cytotoxic to
epirubicin-resistant cells and could be considered as
an alternative treatment option for patients who do
not respond to epirubicin (Fig. 7b). Collectively, these
data suggest that modification of histone-regulated
pathways represents a key “druggable” target in pa-
tients with epirubicin-resistant breast cancers.
Epirubicin-resistant cell lines were generated by expos-
ing native, non-resistant cell lines to increasing concen-
trations of epirubicin. Interestingly, only a single cell
line, SKBR3, upregulated drug transporters, and this was
associated with cross-resistance to taxanes. Previously,
Hembruff et al. [25] developed epirubicin-resistant
MCF7 cells and established that a specific selection dose
must be surpassed to activate drug transporters. For
MCF7, this critical threshold concentration was around
30 nM [19]. Although this concentration is identical to
the selection dose of our resistant MCF7 cells, MDR was
not upregulated, suggesting a stochastic nature of mo-
lecular events that take place en route to drug resistance.
Importantly, it indicates that there exists a previously
unappreciated MDR-independent mechanism of resist-
ance that should be evaluated for clinical relevance.
Our study revealed that one of those mechanisms in-
volves upregulation of H2A and H2B genes and several
pathways, including epigenetic and cell-cycle pathways.
H2A and H2B histones form octamers with H3 and H4
histones, which participate in packaging of DNA into
nucleosomes [26]. These histones are replication-
dependent and cell-cycle–regulated, increasing 35-fold
in S phase during DNA replication [27]. Thus, elevated
histone transcript levels may be a consequence of a
stalled cell cycle as cells struggle to repair epirubicin-
induced DNA damage. However, because resistant cells
did not stall, we eliminated the possibility that upregu-
lated histone transcripts were a mere reflection of accu-
mulated mRNA.
An alternative explanation, supported by the ability of
HDACi to sensitise resistant cells to epirubicin, is that
upregulation of histones contributed to (1) activation of
resistance pathways, (2) silencing of molecular pathways
that sensitise cells to anthracyclines, and/or (3) de-
creased accessibility of epirubicin to DNA. H3 and H4
histone modification patterns strongly associate with
either active or repressed gene transcriptional status.
Current understanding of H2A and H2B histone modifi-
cations is based on studies in yeast and few tumour cell
(See figure on previous page.)
Fig. 5 Histone gene knockdown is not sufficient to resensitise breast cancer cells to epirubicin. a A total of 7 × 104 ZR75-1 epirubicin-resistant
(EpiR) cells and MDA-MB-231 EpiR cells were transfected with 30 nM of each siRNA (Dharmacon; GE Healthcare, Lafayette, CO, USA) targeting
HIST1H2AC and HIST1H2BK (individual knockdowns not shown for simplicity). Negative controls included media only, Lipofectamine only or mock
transfection with non-targeting siRNA. Percentage gene expression knock-down is shown in Additional file 1: Table S3. b IC50 values were
generated using non-linear regression analysis, and average values of two independent experiments are graphed. Error bars represent standard
deviation. c Fold changes in gene expression of each histone variant relative to the housekeeping gene, RPL37A. d-e Histone knockdown effects on
cell cycle and apoptosis for MDA-MB-231 and ZR-75-1. Tables show average percentages of cells in G1, S and G2 stages of cell cycle, and precent live
versus dead cells in each experimental and control condition. Numbers in parenthesis indicate standard deviation between two experiments
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lines; nonetheless, a few important features of H2A and
H2B histone modifications have been revealed. First,
modified sites are acetylated, phosphorylated and ubiqui-
tinated, but not methylated [28–30], a modification most
commonly observed with H3 and H4 histones. This
highlights the appropriate use of HDACi in our study
and their potency due to numerous acetylation sites,
although this does not eliminate the possibility that the
inhibitors were acting on H3 and H4 histones as well.
Because acetylated sites on H2A and H2B are associated
with transcriptional activation [28, 29], modifying the
acetylation pattern may have activated transcriptional re-
pressors and pro-apoptotic genes outlined in our model
(Fig. 7c, point 1, left). Second, the N-terminal ends of
H2A and H2B histones possess a repression domain that
inactivates gene transcription in approximately 10 % of
(See figure on previous page.)
Fig. 6 Histone module is a biological marker for anthracycline therapy. High expression and low expression of histone module were tested for
association with distant recurrence-free survival (DRFS) and overall survival (OS) in the BR9601 trial, in which patients were treated with standard
chemotherapy (CMF) or anthracycline-containing chemotherapy (E-CMF). a DRFS and OS for patients treated with E-CMF vs. CMF split into high
or low histone gene expression groups. b Multivariate, treatment by marker analysis after adjustment for human epidermal growth factor receptor
2 (HER2) status, oestrogen receptor (ER) status, nodal status, grade and age. HR hazard ratio, CI confidence interval
Fig. 7 Histone deacetylase inhibitors (HDACi) induce cytotoxicity in epirubicin-resistant (EpiR) cell lines. a An example of the effect of panobinostat
on all cell lines. Half-maximal inhibitory concentration values for panobinostat and the remaining HDACi are shown in Additional file 1: Table S4.
b A schematic indicating that HDACi could offer a viable treatment option for patients who do not respond to anthracyclines (high histone score).
In addition, patients with low histone score who would initially benefit from epirubicin treatment may in due course develop de novo resistance,
and, if diagnosed with “high histone score” at recurrence, may be offered HDACi as a subsequent treatment option. c Working models of molecular
mechanisms involved in epirubicin resistance. There are three proposed mechanisms by which HDACi sensitise cells to epirubicin: (1) by transcriptional
activation of repressors and pro-apoptotic genes, (2) by repression of resistance genes and (3) due to increased accessibility to DNA
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the yeast genome [28, 29], suggesting that these domains
could have collaborated with acetylation patterns in-
duced by HDACi to repress genes involved in resistance,
such as those involved in cell cycle or apoptosis (Fig. 7c,
point 2, centre). Third, our model also recognises that
resistance might have been reversed by an increased ac-
cessibility of epirubicin to DNA (Fig. 7c, point 3, right).
Interestingly, although the cell lines were resistant, in-
creasing epirubicin concentrations were ultimately cyto-
toxic to the cells, being indicative of partial drug
resistance. This could be a consequence of dynamic
changes in the population that is heterogeneous in terms
of mutations [31] and the ability to use different resist-
ance mechanisms at increasing concentrations of epiru-
bicin until toxic levels are reached. Alternatively, a non-
mutation–driven model might have contributed to the
partial resistance to epirubicin; that is, because the rate
of cell kill is proportional to the rate of tumour growth
[32, 33], the effectiveness of epirubicin might have
depended on the proportion of cells that were actively
dividing vs. those that were in G0 phase and unrespon-
sive to the drug treatment until they entered the G1
phase of the cell cycle [31].
Regel et al. [34] showed that the HDACi panobinostat
sensitises gastric cancer cells to anthracyclines. Our find-
ings are consistent with those of their study and show
that multiple HDACi reverse anthracycline resistance in
breast cancer cells. This is an important finding because
many of the pharmacological inhibitors tested in our
study are in use either as single agents or as combin-
ation therapies in phase II/III clinical trials [35–37].
HDACi currently in clinical trials include panobinostat,
quisinostat, givinostat, abexinostat, pracinostat, belinostat
and mocetinostat (Additional file 1: Table S4). Because
anthracycline resistance may lead to cross-resistance to
taxanes [2, 38], as it did in one of our resistant cell lines, it
may be that taxanes, not anthracyclines, should be used in
first-line treatment [39]. Furthermore, the patients in this
study received polychemotherapy as part of their standard
of care and, as was appropriate at the time, received either
CMF (standard of care at the time) or anthracyclines
(experimental at the time). Given the focus of our research
on identifying markers of anthracycline benefit, this trial
design satisfies the requirement of Simon et al. for a bio-
marker validation study [40]; however, further research in
the context of taxane-based chemotherapy would be of
value. As cancer cells could acquire resistance to HDACi
[36], sequential therapy involving HDACi, taxanes and
anthracyclines will be an important aspect of clinical trial
design and medical practice.
Conclusions
We have developed a relevant model for studying clin-
ical resistance and a model that could be used for
developing and testing novel single or combination
breast cancer therapies. Importantly, we have identified
novel pathways containing histone H2A and H2B genes
as a mechanism of drug resistance across a spectrum of
breast cancer cell lines and validated this finding in the
BR9601 adjuvant clinical trial cohort. Although further
validation studies are necessary, the use of HDACi holds
promise for patients whose breast cancers do not re-
spond to anthracycline-containing chemotherapy.
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